China's National Medical Products Administration accepted the clinical trial application of Shanghai RAAS Blood Products' (SHE:002252) subsidiary, Guangxi RAAS Biopharmaceutical, for protein C, according to a Shenzhen bourse filing over the weekend.
The product is used for the treatment of patients with congenital protein C deficiency, including the treatment of acute thrombosis and prevention of thrombosis.